source
- Skyhawk reports functional gains in Huntington's disease trial of RNA-splicing pillSkyhawk Therapeutics, a Boston biotech backed by Fidelity, released final data from a small mid-stage trial of its once-daily RNA-splicing pill for Huntington's disease. After 15 months, patients…
- Novartis scraps TREM2 ALS candidate after Phase 2 failureNovartis announced it is halting development of its TREM2-targeting drug VHB937, also known as lifonebart, after the Phase 2 trial in amyotrophic lateral sclerosis (ALS) did not meet its primary en…